A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

August 12, 2019

Primary Completion Date

April 26, 2021

Study Completion Date

April 26, 2021

Conditions
Atopic Dermatitis
Interventions
DRUG

RPT193

Antagonist of the CCR4 chemokine receptor

DRUG

Placebo

Matching placebo

Trial Locations (14)

10075

Sadick Research Group LLC, New York

33172

Lenus Research & Medical Group, Miami

33613

ForCare Clinical Research, Tampa

36207

Pinnacle Research Group, LLC, Anniston

46250

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

70006

Clinical Trials Management,LLC, Metairie

70809

DelRicht Research, Baton Rouge

73071

Central Sooner Research, Norman

78213

Progressive Clinical Research PA, San Antonio

78759

DermResearch, Inc., Austin

85254

Perseverance Research Center LLC, Scottsdale

92123

University Clinical Trials, Inc, San Diego

02135

MetroBoston Clinical Partners LLC, Brighton

9728 NZ

PRA, Groningen

All Listed Sponsors
lead

RAPT Therapeutics, Inc.

INDUSTRY

NCT04271514 - A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter